Atrion Co. (NASDAQ:ATRI – Get Free Report) saw a large decrease in short interest during the month of June. As of June 30th, there was short interest totalling 60,100 shares, a decrease of 20.2% from the June 15th total of 75,300 shares. Currently, 4.4% of the company’s stock are sold short. Based on an average trading volume of 32,100 shares, the short-interest ratio is presently 1.9 days.
Hedge Funds Weigh In On Atrion
A number of hedge funds have recently made changes to their positions in ATRI. Citizens Financial Group Inc. RI purchased a new stake in shares of Atrion in the fourth quarter worth approximately $1,114,000. Penn Mutual Asset Management LLC purchased a new stake in shares of Atrion during the fourth quarter valued at $1,949,000. Jump Financial LLC bought a new position in shares of Atrion in the fourth quarter worth about $234,000. Tower Research Capital LLC TRC increased its stake in Atrion by 592.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 231 shares during the period. Finally, Quadrant Capital Group LLC bought a new stake in Atrion during the 4th quarter valued at about $36,000. Institutional investors own 66.19% of the company’s stock.
Atrion Trading Up 0.1 %
NASDAQ ATRI traded up $0.40 during trading on Monday, hitting $456.00. The company had a trading volume of 15,313 shares, compared to its average volume of 23,366. Atrion has a one year low of $274.98 and a one year high of $593.00. The company’s fifty day moving average is $454.15 and its 200-day moving average is $409.47. The company has a market cap of $802.56 million, a price-to-earnings ratio of 42.82 and a beta of 0.68.
Atrion Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Friday, June 14th were paid a $2.20 dividend. The ex-dividend date of this dividend was Friday, June 14th. This represents a $8.80 annualized dividend and a dividend yield of 1.93%. Atrion’s dividend payout ratio (DPR) is 82.71%.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on Atrion in a research report on Tuesday, July 9th. They set a “sell” rating on the stock.
Check Out Our Latest Research Report on ATRI
Atrion Company Profile
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Read More
- Five stocks we like better than Atrion
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- How is Compound Interest Calculated?
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.